For Physicians

The Clear Cell Sarcoma Foundation is committed to helping bring together physicians knowledgeable about Clear Cell Sarcoma. We want to partner with physicians to offer support and connection with other physicians as well as CCS patients. Since CCS is ultra-rare, it is difficult to access up-to-date information quickly. CCS patients and caregivers have participated in FDA listening sessions, Focus Groups and Industry webinars. CCS is our main focus so please reach out to us, we are here for you.

Clear Cell Sarcoma Physician Resources

Clear cell sarcoma (CCS) is an ultra-rare cancer with no established standard of care and limited clinical trial data. To support oncologists and researchers, the Clear Cell Sarcoma Foundation has developed a series of concise, literature-based resources of available treatments and disease features.
These include a new summary of the 2025 Ibero-American Consensus for the Management of Liver Metastases of Soft Tissue Sarcoma, providing international guidance relevant to CCS cases where the liver is a site of metastasis.
In addition, a detailed white paper provides a comprehensive review of chemotherapy use in CCS.
Surgery remains the standard of care for CCS and offers the best chance for durable disease control whenever possible. Systemic therapies may be considered when surgery is not feasible, when clear margins are not achieved, or in the setting of metastatic disease, but to date they have shown only limited effectiveness.
Disclaimer: The Clear Cell Sarcoma Foundation provides summaries of published evidence and expert consensus for educational purposes. These materials do not constitute medical advice, clinical directives, or treatment recommendations. Clinical decisions should be made based on each patient's individualized circumstances, the treating clinician's judgement, and current standards of care.

For further information, please contact CCSF's Scientific Director, Kelley Argraves, at kelley@clearcellsarcoma.org.

Quick Reference Summaries

Chemotherapy in CCS

Clear Cell Sarcoma Metastasis

Tyrosine Kinase Inhibitors

Sunitinib (Sutent®)

Immune Checkpoint Inhibitors

Tebentafusp

Devimistat

CCS Therapies Overview

Liver Metastasis Summary

Expanded Resource

This white paper is an evidence-based review of chemotherapy in CCS that examines available data on outcomes and harms, explains why chemotherapy persists despite limited efficacy, and details the ethics of informed consent. It provides practical information to support decision-making for clinicians and patients while recommending steps toward disease-specific treatment guidelines and expanded access to more appropriate alternatives.

Toward Better Care in CCS

Clinical Trials

Here are the Clinical Trials from National Institute of Health focused on Clear Cell Sarcoma. SARC (Sarcoma Alliance for Research through Collaboration) will occasionally post active trials on CCS as well.

60d13a6607e619546906d5db_Publication-ico

Publications

Publications helpful in understanding Clear Cell Sarcoma.

NCCN Guidelines

Our team is constantly checking and ensuring we have the latest and most accurate guideline for Soft Tissue Sarcoma, specifically on Clear Cell Sarcoma.

Physician Login

Once logged in, Type Clear Cell Sarcoma in the search box to expedite results.

Clear Cell Sarcoma 101

A brief summary of current CCS information.

CCSF Team Showcases Groundbreaking Research at CTOS 2023, 2024 & 2025

The CCSF research team made significant contributions to the Connective Tissue Oncology Society (CTOS) annual meetings, presenting three innovative poster presentations in 2023, 2024 and 2025. These presentations highlighted our ongoing commitment to advancing Clear Cell Sarcoma research and improving patient outcomes through scientific discovery.

Our work at these prestigious oncology conferences demonstrates CCSF's leadership in rare cancer research and our dedication to sharing critical findings with the global oncology community.